Comparison of Medium- and High-Energy Collimators for 131I-Tositumomab Dosimetry
نویسندگان
چکیده
منابع مشابه
131I–Tositumomab in lymphoma
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of (131)I-tositumomab in non-Hodgkin lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns about associated toxicities and unclear long...
متن کاملCharacterization of low, medium and high energy collimators for common isotopes in nuclear medicine: A Monte Carlo study
Introduction:In an ideal parallel-hole collimator, thickness of septal material should be sufficient to stop more than 95% of incident photons. However, some photons pass the septa without interaction or experience scattering before they reach the detector. In this study, we determined different contribution of collimator responses consist of geometrical response, septal penetr...
متن کاملcomparison of zoe and vitapex for canal treatment of necrotic primary teeth
چکیده ندارد.
15 صفحه اولUpdate on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
UNLABELLED A study of the use of (131)I-labeled tositumomab, preceded by an unlabeled tositumomab predose, for therapy of 76 previously untreated non-Hodgkin's lymphoma patients has been completed at the University of Michigan. Fifty-two of the 76 treated patients were imaged once during therapy with SPECT to assist in dosimetric estimation. In this article, the patient's average tumor dose, es...
متن کاملComparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
UNLABELLED We retrospectively evaluated our single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We evaluated the hypothesis that the patient-specific dosing regimen used with (131)I-tositumomab results in less bone marrow toxicity than does the weight-based dosing regimen used with (90)Y-ibritumomab tiu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine Technology
سال: 2007
ISSN: 0091-4916
DOI: 10.2967/jnmt.106.038174